January 07, 2026

The U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) has released its Fiscal Year 2026 guidance priorities, outlining the regulatory topics, policy updates, and emerging technologies expected to shape the future of medical device compliance in the United States.

For medical device manufacturers, the FDA’s annual guidance agenda provides critical insight into:

  • Upcoming regulatory expectations 
  • Evolving submission requirements 
  • Emerging compliance risks 
  • New technology oversight areas 
  • Future inspection and review priorities 

As software-driven technologies, AI-enabled devices, digital health platforms, and data-driven clinical evidence continue expanding across the healthcare industry, the FDA is increasing focus on lifecycle risk management, software governance, cybersecurity, real-world evidence (RWE), and Quality Management System (QMS) alignment.

Manufacturers that proactively align with CDRH guidance priorities will be better positioned to:

  • Accelerate market access 
  • Reduce FDA deficiency responses 
  • Improve submission quality 
  • Strengthen inspection readiness 
  • Minimize regulatory delays 

This comprehensive guide by Maven Regulatory Solutions explains the FDA CDRH FY2026 guidance priorities, major regulatory themes impacting medical device manufacturers, and strategic actions companies should take to remain compliant and competitive.

Understanding The FDA CDRH Guidance Planning Structure

The FDA organizes its annual guidance development roadmap into three priority categories.

1. A-List Guidance Documents

The A-List includes high-priority guidance documents that the FDA intends to publish or advance during FY2026.

Important Note:

A-List Topics Often Signal Immediate Regulatory Focus Areas

These guidance documents typically affect:

  • Active FDA reviews 
  • Submission expectations 
  • Inspection priorities 
  • Emerging technology oversight 

2. B-List Guidance Documents

The B-List includes guidance topics the FDA will work on if additional resources become available.

Why B-List Matters

B-List topics often indicate:

  • Future regulatory direction 
  • Emerging policy priorities 
  • Areas under increasing FDA scrutiny 

Many B-List topics eventually evolve into major regulatory expectations.

3. Under Construction (UC) Guidance Topics

The Under Construction (UC) category includes longer-term guidance projects still under development.

These topics provide valuable forecasting into:

  • Future compliance trends 
  • Emerging technology regulation 
  • Long-term FDA policy evolution 

Major FDA CDRH Guidance Priorities

The FY2026 roadmap highlights several regulatory areas expected to significantly impact medical device manufacturers.

A-List Guidance Priorities Expected to Impact Manufacturers

1. Device Software Functions (Draft Guidance)

Software-driven devices remain one of the FDA’s highest regulatory priorities.

Areas Expected to Be Addressed

  • Software classification updates 
  • SaMD oversight expansion 
  • Software lifecycle documentation 
  • Risk-based software evaluation 
  • Connectivity and interoperability 
  • Cybersecurity integration 

Important Industry Shift:

Software Is Increasingly Regulated as A Core Medical Device Function Not A Supporting Feature

This guidance may significantly impact:

  • Software-as-a-Medical-Device (SaMD) 
  • AI-enabled systems 
  • Mobile health applications 
  • Connected healthcare platforms 
  • Cloud-integrated diagnostics 

2. Quality Management System (QMS) Information for Premarket Submissions

The FDA continues aligning its Quality Management System Regulation (QMSR) with ISO 13485 principles.

Devices Potentially Affected

  • 510(k) 
  • PMA 
  • De Novo 
  • PDP submissions 

Expected FDA Focus Areas

  • Risk management integration 
  • Design control documentation 
  • CAPA traceability 
  • Supplier management 
  • QMS consistency 
  • Inspection readiness 

Critical Compliance Point:

Manufacturers Must Prepare for Greater Alignment Between Premarket Submissions and QMS Documentation

3. Real-World Evidence (RWE) Revisions

The FDA continues expanding the use of Real-World Evidence in regulatory decision-making.

RWE May Be Used For

  • Premarket submissions 
  • Postmarked surveillance 
  • Device performance monitoring 
  • Clinical evidence support 
  • Safety signal analysis 

Key Regulatory Trend:

The FDA Is Increasingly Moving Toward Data-Driven Lifecycle Oversight

Manufacturers should strengthen:

  • Data integrity controls 
  • Real-world data governance 
  • Evidence traceability 
  • Clinical analytics frameworks 

4. Validation Of Diagnostic Tests for Emerging Pathogens

This guidance reflects the FDA’s growing focus on public health preparedness and rapid diagnostic validation.

Likely Areas Of Focus

  • Analytical validation 
  • Clinical performance 
  • Emergency response readiness 
  • Diagnostic sensitivity & specificity 
  • Flexible validation pathways 

This is particularly important for:

  • IVD manufacturers 
  • Molecular diagnostics 
  • Infectious disease testing companies 

B-List Guidance Priorities 

Artificial Intelligence (AI) Lifecycle Management – Final Guidance

One of the most anticipated guidance topics is AI/ML lifecycle management.

Expected Areas of Clarification

  • Algorithm training requirements 
  • Data quality expectations 
  • Bias mitigation 
  • Change control protocols 
  • Real-time learning systems 
  • Data drift monitoring 
  • Postmarked AI oversight 

Important FDA Direction:

AI Regulation Is Moving Toward Continuous Lifecycle Governance Rather Than Static Validation

This guidance may reshape regulatory expectations for AI-enabled medical devices globally.

Additional B-List Topics Include

  • Weight-loss medical devices 
  • Human factors engineering documentation 
  • Usability validation requirements 

These reflect increasing FDA focus on patient-centered safety and usability.

Under Construction (UC) Guidance Topics

The UC category contains several strategically important long-term regulatory topics.

1. Intended Use of Medical Devices

The FDA is developing guidance related to:

  • Intended use interpretation 
  • Substantial equivalence limitations 
  • Labeling claims 
  • Device classification strategy 

Critical Regulatory Impact:

Intended Use Language Can Directly Influence FDA Clearance Pathways

Manufacturers should carefully evaluate:

  • Marketing claims 
  • Device indications 
  • Predicate device comparisons 
  • Clinical justification strategies 

2. Evaluation Of Thermal Effects

Thermal safety remains an increasing concern for modern technologies.

Devices Potentially Impacted

  • Wearables 
  • RF devices 
  • Energy-based surgical tools 
  • Implantable technologies 
  • Consumer health technology 

FDA Focus Areas May Include

  • Tissue heating risks 
  • Energy exposure thresholds 
  • Long-term thermal safety 
  • Validation testing protocols 

3. Robotically Assisted Surgical Devices

The FDA continues increasing oversight over robotic and automated surgical systems.

Key Areas Likely To Be Evaluated

  • Human-machine interaction 
  • Automation safety 
  • Software reliability 
  • Cybersecurity controls 
  • Clinical performance validation 

Industry Trend:

Advanced Robotics & Automation Are Becoming Major FDA Oversight Priorities

Comparing FY2025 vs FY2026 Guidance Trends

Reviewing prior-year guidance execution provides important regulatory forecasting insights.

Key FY2025 Observations

  • Only approximately 35% of planned A-List guidance documents were finalized 
  • Many B-List topics remain under development 
  • Numerous unplanned guidance documents were issued during FY2025  
  • Public health priorities significantly influenced FDA resource allocation 

What This Means for Manufacturers

The FDA guidance agenda is:

  • Dynamic 
  • Risk-based 
  • Technology-driven 
  • Responsive to emerging events 

Important Strategic Point:

Manufacturers Must Treat FDA Guidance Plans as Directional Not Fixed Timelines

Continuous regulatory intelligence monitoring is essential.

Key Regulatory Themes Emerging in FY2026

Several major themes are becoming increasingly clear across FDA guidance priorities.

1. Increased Oversight of Software & Digital Health

The FDA continues expanding regulation of:

  • AI-enabled software 
  • Connected devices 
  • Cybersecurity 
  • SaMD platforms 
  • Cloud-based medical technologies 

2. Greater Emphasis on Lifecycle Risk Management

Manufacturers are increasingly expected to demonstrate:

  • Continuous monitoring 
  • Real-world evidence integration 
  • Postmarked surveillance maturity 
  • Risk-based decision frameworks 

3. Stronger QMS & Documentation Alignment

The FDA is moving toward tighter integration between:

  • Premarket submissions 
  • Quality systems 
  • Design controls 
  • CAPA processes 
  • Supplier oversight 

4. Expanded Transparency & Traceability Expectations

Manufacturers may face increasing expectations around:

  • Data governance 
  • Software traceability 
  • Clinical evidence integrity 
  • Documentation consistency 

Strategic Actions Manufacturers Should Take Now

Recommended Preparation Steps

Monitor FDA Guidance Updates Continuously

Track:

  • New draft guidance 
  • Final guidance publications 
  • FDA webinars 
  • CDRH announcements 
  • Public workshop discussions 

Review of Product Portfolios Against A-List Priorities

Evaluate whether your products involve:

  • AI functionality 
  • Software-driven features 
  • Cybersecurity risks 
  • Diagnostic technologies 
  • Connected systems 

Strengthen Submission Documentation

Enhance:

  • Software documentation 
  • Risk management files 
  • Clinical evidence 
  • Cybersecurity controls 
  • QMS traceability 

Prepare For AI Governance Expectations

AI-enabled device manufacturers should proactively address:

  • Bias management 
  • Data quality 
  • Model monitoring 
  • Change control procedures 
  • Lifecycle governance frameworks 

Evaluate Intended Use Strategies Carefully

Review:

  • Product claims 
  • Labeling consistency 
  • Predicate alignment 
  • Regulatory positioning 

Quick FY2026 FDA Guidance Facts

  • Software oversight remains a major FDA priority 
  • AI lifecycle governance is rapidly evolving 
  • QMSR alignment continues expanding 
  • RWE use is increasing across submissions 
  • Intended use scrutiny is intensifying 
  • Cybersecurity expectations continue growing 
  • Postmarket lifecycle management is becoming more important 
  • FDA priorities remain highly dynamic and technology-driven 

Risks Of Failing to Align with FDA Guidance Trends

Manufacturers that fail to adapt to evolving CDRH priorities may experience:

  • FDA deficiency letters 
  • Submission delays 
  • Additional information requests 
  • Longer review timelines 
  • Increased compliance costs 
  • Inspection observations 
  • Regulatory uncertainty 
  • Delayed market access 

Critical Industry Reality:

Proactive Regulatory Alignment Reduces Long-Term Submission & Compliance Risk

How Maven Regulatory Solutions Supports FDA Device Strategy

Our Services

  • FDA regulatory strategy development 
  • 510(k), PMA & De Novo submission support 
  • Q-Submission preparation 
  • Software & AI regulatory consulting 
  • QMSR readiness assessments 
  • Cybersecurity compliance strategy 
  • Intended use and labeling reviews 
  • Regulatory intelligence monitoring 
  • Gap assessments for FDA guidance updates 
  • End-to-end U.S. market entry support 

Why Choose Maven

  • Deep FDA regulatory expertise 
  • Strong medical device industry experience 
  • Practical submission-focused strategies 
  • Cross-functional compliance capabilities 
  • Risk-based regulatory planning approach 
  • Global regulatory alignment support 

Learn more at Maven Regulatory Solutions.

Preparing For FDA CDRH FY2026 Regulatory Changes?

Whether your organization is developing AI-enabled technologies, strengthening software documentation, preparing for QMSR transition, improving cybersecurity compliance, or aligning with evolving FDA submission expectations, Maven Regulatory Solutions can help.

Contact Maven Regulatory Solutions For:

  • FDA regulatory strategy consulting 
  • 510(k), De Novo & PMA support 
  • AI & software regulatory guidance 
  • QMSR readiness preparation 
  • Cybersecurity documentation support 
  • Intended use & labeling strategy 
  • FDA gap assessments 
  • Regulatory intelligence monitoring 

Visit Maven Regulatory Solutions to connect with our FDA medical device regulatory experts.

Conclusion

The FDA CDRH FY2026 guidance priorities clearly signal increasing regulatory focus on:

  • Software-driven devices 
  • AI-enabled technologies 
  • Cybersecurity governance 
  • Lifecycle risk management 
  • Real-world evidence integration 
  • QMS alignment 
  • Advanced diagnostics and automation 

As regulatory expectations continue evolving rapidly, manufacturers must adopt proactive, flexible, and intelligence-driven compliance strategies to remain competitive and inspection-ready.

Organizations that align early with emerging FDA guidance priorities will be better positioned to accelerate approvals, reduce regulatory risk, strengthen product quality, and maintain long-term market success.

Maven Regulatory Solutions helps medical device companies transform evolving FDA expectations into strategic regulatory advantages.

Frequently Asked Questions

Q1. What is the FDA CDRH A-List?

The A-List contains the FDA’s highest-priority guidance documents expected to be published or advanced during the fiscal year.

Q2. Why are FDA priorities important for manufacturers?

They provide insight into evolving FDA expectations, submission trends, and future compliance requirements.

Q3. Will AI-enabled devices face greater FDA scrutiny in FY2026?

Yes. AI lifecycle management, monitoring, validation, and postmarket oversight remain major FDA focus areas.

Q4. What is QMSR?

QMSR is the FDA’s updated Quality Management System Regulation aligned more closely with ISO 13485 principles.

Q5. How does intended use of guidance affect submissions?

Intended use of language can impact device classification, substantial equivalence strategy, and regulatory pathway selection.

Q6. Are software-driven devices a major FDA focus?

Yes. Software functions, cybersecurity, connectivity, and lifecycle governance are among the FDA’s top priorities.

Q7. How can Maven Regulatory Solutions support FY2026 compliance readiness?

Maven provides FDA strategy consulting, submission support, regulatory intelligence, AI/software compliance guidance, and QMS readiness services.